AIM ImmunoTech

AIM · NYSE American

$0.1662+$0.0031 (+1.90%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $0.1631

AIM analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $4.34 (+2508.3% upside)

Low: $1.51
Now: $0.1662
High: $7.35

Upgrades and downgrades

The latest rating actions, newest first

AIM analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Ascendiant Capital	Aug 20, 2026	Maintains	Buy	$9.00 → $7.00	28%
Ascendiant Capital	Jun 1, 2026	Maintains	Buy	$10.00 → $9.00	28%
Ascendiant Capital	Apr 10, 2026	Maintains	Buy	$22.00 → $10.00	28%
Ascendiant Capital	Dec 8, 2025	Maintains	Buy	$24.00 → $22.00	28%

The case for and against

Updated Oct 21, 2026

Bull case

AIM ImmunoTech is supported by a promising oncology platform centered on Ampligen, which is being tested in combination with checkpoint blockade therapies at multiple major U.S. cancer research centers to improve tumor responses, time to progression, and survival. The investment case is strengthened by the company’s large upside opportunity, with the cited billion-dollar market potential offsetting the roughly 2-year development road left for its oncology programs. Near-term sentiment is also helped by the anticipation of additional clinical data over the next year, with initial and recent results already positive and the new focus on pancreatic cancer progress seen as an important catalyst for the stock.

Bear case

AIM ImmunoTech is a clinically early, revenue-light biotech whose investment case remains highly speculative because its value depends on successful trial outcomes, regulatory approvals, commercialization, and reimbursement, all of which are uncertain. The company’s reported Q1 2026 loss of $3.0 million, or $(0.69) per share, underscores continued operating losses despite beating estimates, while the absence of guidance limits visibility into future execution. With explicit balance sheet and liquidity risks, plus exposure to competition, macro pressure, and volatile biotech sentiment, the fundamental profile supports a negative outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.